Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sharma, Kumar, M.D.
With
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetic kidney disease is the leading cause of new cases of kidney failure in the United States. In the kidneys of diabetic patients, there is accumulation of protein that leads to the formation of scar tissue and poor kidney function. Because of this many patients eventually require dialysis or kidney transplantation. A new investigational drug, pirfenidone, has been shown to be beneficial in a number of diseases in which scar formation leads to disease progression. It is our goal to examine whether pirfenidone is effective at stabilizing or reducing progressive diabetic kidney dysfunction.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Inclusion
Type 1 or type 2 diabetes
Males and females greater than or equal to 18 years.
Abnormal kidney function determined by glomerular filtration rate
History of proteinuria
Blood pressure controlled to \<140/90 on anti-hypertensive medication
Exclusion
Cancer, liver disease, hepatitis, HIV+
History of heart attack, unstable angina, stroke or peptic ulcer in the past 6 months
Pregnant or planning to become pregnant during the study period
Other known kidney disease besides diabetic nephropathy
Expect to begin dialysis or receive a kidney transplant within 1 year of study enrollment